New technique to aid diagnosis of glycosylation disorders present at birth

28 Jun 2016, 2:21 p.m.

Researchers

A study, supported by the NIHR Great Ormond Street BRC, investigated the use of a 2D-differential gel electrophoresis (DIGE) method that provides a global analysis of the serum glycoproteome (glycomic profiling). 2D-DIGE allows multiple samples to be run simultaneously, eliminating gel-to-gel variations, and allowing direct overlay comparisons.

The results showed that for some CDG patients not all glycoproteins were consistently affected. The results identified several new and specific markers of N- and O-linked glycoproteins, never before described. These proteins were shown to be changed in patients, something that conventional tests failed to identify. The findings showed that 2D DIGE is an ideal method for investigation of the global glycoproteome and it could aid diagnosis and sub classification of complex CDG cases, with the potential to identify new diseases. This work was supported by the NIHR GOSH BRC and findings have been published in Molecular Genetics and Metabolism reports.

Congenital disorders of glycosylation (CDG) are a group of rare genetic, metabolic disorders caused by an error in glycosylation. There are over 60 different CDG identified, resulting in a broad range of clinical symptoms, making initial clinical assessment challenging. Screening of CDG is currently based on the investigation of the glycoproteins transferrin and apolipoprotein CIII. However, this cannot diagnose all potential defects in the glycosylation pathway and overlooks new inborn errors of metabolism, resulting in more subtle defects being missed.

Fourth Annual NIHR GOSH BRC Image Competition - A Moment of Discovery

The Research and Innovation Communications team at GOSH and the NIHR GOSH Biomedical Research team invite you to enter our Research and Innovation Showcase: A Moment of Discovery.

GOSH pilots AI tool to give clinicians more quality-time with patients

Patients and clinicians at GOSH have been taking part in the first NHS trial of a bespoke healthcare AI assistant, TORTUS, to help increase face-to-face time during appointments.

New hope to prevent blindness in children with rare genetic disease

A new treatment that could prevent blindness in children with the CLN2 type Batten disease has been trialled by Clinicians at GOSH and University College London Great Ormond Street Institute of Child Health (UCL GOS ICH).

GOSH only hospital outside of North America to receive innovation funding award for AI

GOSH has been awarded the Amazon Web Services IMAGINE Grant: Children’s Health Innovation Award, to support artificial intelligence (AI) development and drive progress for children’s healthcare.